The Board of Aurobindo Pharma at its meeting held on 18 July 2024 has approved buyback of up to 51,36,986 equity shares of the company at a price of Rs 1,460 per share for a aggregate amount of up to Rs 750 crore. Powered by Capital Market - Live News

Aurobindo Pharma will hold a meeting of the Board of Directors of the Company on 18 July 2024.Powered by Capital Market - Live News

Net profit of Aurobindo Pharma rose 79.50% to Rs 908.75 crore in the quarter ended March 2024 as against Rs 506.27 crore during the previous quarter ended March 2023. Sales rose 17.45% to Rs 7491.92 crore in the quarter ended March 2024 as against Rs 6378.67 crore during the previous quarter ended March 2023.For the full year,net profit rose 64.62% to Rs 3172.97 crore in the year ended March 2024 as against Rs 1927.50 crore during the previous year ended March 2023. Sales rose 16.60% to Rs 28704.50 crore in the year ended March 2024 as against Rs 24617.13 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales7491.926378.67 17 28704.5024617.13 17 OPM %22.1615.62 -20.3015.06 - PBDT1706.341075.63 59 6093.513857.08 58 PBT1352.01730.06 85 4571.852612.50 75 NP908.75506.27 79 3172.971927.50 65 Powered by Capital Market - Live News

Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) had conducted an inspection at Unit III, a Formulation manufacturing facility, of Eugia Pharma Specialities, a wholly owned subsidiary of the Company, situated at Pashamylaram, Patancheru Mandal, Sangareddy District, Telangana, from 22 January to 2 February 2024. Subsequently, the US FDA has determined the inspection classification status of this facility as �Official Action Indicated (OAI)`.The company remains committed to work closely with the US FDA and continues to enhance its compliance on an ongoing basis.Powered by Capital Market - Live News

Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) inspected Unit-VII, an API manufacturing facility, of Apitoria Pharma, a wholly owned subsidiary of the Company, situated at Parwada Mandal, Anakapally District, Andhra Pradesh from 05 May to 10 May 2024.The inspection closed with 1 observation. The observation is of procedural in nature and will be responded to within the stipulated time. Powered by Capital Market - Live News